INCYTE CORP stock analysis

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chro

Ticker: INCY
Exchange: Nasdaq
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded INCYTE CORP at 119.14 USD on 2026-11-05T18:28:57.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2021-11-04 through 2026-10-14 across 1208 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying INCYTE CORP stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.